Why Do Most People Who Stop A GLP-1 Medication Go Back Within Two Years?
Most people who stop don't stay stopped.
That is the answer before the explanation.
A large cohort study following more than 125,000 adults after they began GLP-1 treatment found that most discontinued within a year or two — but a substantial share came back. Within two years of stopping, 46.4% of patients without type 2 diabetes and 57.3% of those with type 2 diabetes had reinitiated treatment (Rodriguez et al., 2025). Stopping, in other words, is frequently not an ending. It's a pause with a documented return rate.
What Actually Predicts The Return
The same study found something more specific than a general tendency to restart: the amount of weight regained after stopping directly tracked with how likely someone was to go back. Each additional percentage point of weight regained after discontinuation was associated with a 2.3% to 2.8% higher likelihood of reinitiating treatment (Rodriguez et al., 2025). The body's response during the gap, not just time passing, appears to be doing much of the work in that decision.
That detail matters because it reframes what the "off" period actually is. It isn't simply time away from treatment. It's an active phase with its own trajectory — one that, according to this data, often ends up informing whether someone restarts at all.
Why The Gap Gets Treated As A Non-Event
Most attention, understandably, goes to the treatment itself: the dose, the schedule, the appointment. The period after stopping tends to get treated as a blank space — the part that doesn't need tracking because nothing is technically "happening." But the data suggests the opposite. The gap is where a measurable, decision-relevant pattern unfolds, often without anyone writing down what it looked like along the way.
The Distinction Worth Making
There's a difference between remembering that weight came back and knowing the actual shape of how it came back — how quickly, alongside what appetite changes, over what span of time. The first is a vague impression available to anyone. The second is the kind of detail that would actually inform a restart decision, and it's exactly the kind of detail that tends to disappear without a specific place to keep it.
For the related essay on why treatment-period symptoms are difficult to date accurately from memory, see Why Can't You Remember What Week The Nausea Started?
References
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Goodwin Cartwright, B., Baker, C., Gluckman, T. J., Stucky, N., & Emanuel, E. J. (2025). Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Network Open, 8(1), e2457349.
